Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
作者： R P Abratt , W R Bezwoda , G Falkson , L Goedhals , D Hacking
DOI: 10.1200/JCO.1994.12.8.1535
关键词:
摘要: PURPOSEThe aim of this study was to evaluate the efficacy and toxicity gemcitabine at higher doses than had been used previously in patients with non-small-cell lung cancer (NSCLC).PATIENTS AND METHODSEighty-four (65 men, 19 women; age range, 35 75 years; mean age, 59 years) locally advanced or metastatic pathologically documented NSCLC were enrolled. Patients bidimensionally measurable disease, as defined by computed tomographic (CT) scan chest x-ray. A total 28.6% surgically treated, while 9.5% received radiotherapy. Fifty-three commenced a dose 1,000 mg/m2, 31 1,250 mg/m2. receive two escalations 25%, provided that overall no worse World Health Organization (WHO) grade 1 WHO 0 for platelets. Responding reviewed validated blinded oncology review board (ORB) experts not involved study. Of original 84 enrolled, 76 ass...
sci-hub.se 参考文章(11)
W. Maclaughlin, G. Graham, Z. Arlin, J. Cole, M. Birkhofer, K. Bhalla, Continuously Administered 2',2'-Difluorodeoxycytidine (Dfdc) and Deoxycytidine (Dcyd) - a Potentially Selective Cyto-Toxic Regimen Toward Human-Leukemic Myeloid Progenitors in Culture Proceedings of the American Association for Cancer Research. ,vol. 29, pp. 348- 348 ,(1988)
H Anderson, B Lund, F Bach, N Thatcher, J Walling, H H Hansen, Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. Journal of Clinical Oncology. ,vol. 12, pp. 1821- 1826 ,(1994) , 10.1200/JCO.1994.12.9.1821
J L Abbruzzese, R Grunewald, E A Weeks, D Gravel, T Adams, B Nowak, S Mineishi, P Tarassoff, W Satterlee, M N Raber, A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. Journal of Clinical Oncology. ,vol. 9, pp. 491- 498 ,(1991) , 10.1200/JCO.1991.9.3.491
N. Donnadieu, M. Paesmans, J.-P. Sculier, Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature Lung Cancer. ,vol. 7, pp. 243- 252 ,(1991) , 10.1016/0169-5002(91)90279-F
J. Camichael, U. Fink, R.C.G. Russell, M.F. Spittie, A. Harris, G. Spiessi, J. Blatter, Phase II study of gemcitabine in patients with advanced pancreatic cancer European Journal of Cancer. ,vol. 29, ,(1993) , 10.1016/0959-8049(93)91164-G
Ephraim S. Casper, Mark R. Green, David P. Kelsen, Robert T. Heelan, Thomas D. Brown, Carlos D. Flombaum, Bonnie Trochanowski, Peter G. Tarassoff, Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investigational New Drugs. ,vol. 12, pp. 29- 34 ,(1994) , 10.1007/BF00873232
Gerald B. Grindey, L. W. Hertel, W. Plunkett, Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine). Cancer Investigation. ,vol. 8, pp. 313- 314 ,(1990) , 10.3109/07357909009017602
Y. Cormier, E. Eisenhauer, A. Muldal, R. Gregg, J. Ayoub, G. Goss, D. Stewart, P. Tarasoff, D. Wong, Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group Annals of Oncology. ,vol. 5, pp. 283- 285 ,(1994) , 10.1093/OXFORDJOURNALS.ANNONC.A058808
B. Lund, O. P. Hansen, K. Theilade, M. Hansen, J. P. Neijt, Phase II Study of Gemcitabine (2′,2′-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients Journal of the National Cancer Institute. ,vol. 86, pp. 1530- 1533 ,(1994) , 10.1093/JNCI/86.20.1530
Larry W. Hertel, William K Plunkett, Gerald B. Grindey, Volker Heinemann, Comparison of the Cellular Pharmacokinetics and Toxicity of 2′,2′-Difluorodeoxycytidine and 1-β-d-Arabinofuranosylcytosine Cancer Research. ,vol. 48, pp. 4024- 4031 ,(1988)